Literature DB >> 12594303

Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.

William J Murphy1, Lisbeth Welniak, Timothy Back, Julie Hixon, Jeff Subleski, Naoko Seki, Jon M Wigginton, Susan E Wilson, Bruce R Blazar, Anatoli M Malyguine, Thomas J Sayers, Robert H Wiltrout.   

Abstract

In cancer, the coordinate engagement of professional APC and Ag-specific cell-mediated effector cells may be vital for the induction of effective antitumor responses. We speculated that the enhanced differentiation and function of dendritic cells through CD40 engagement combined with IL-2 administration to stimulate T cell expansion would act coordinately to enhance the adaptive immune response against cancer. In mice bearing orthotopic metastatic renal cell carcinoma, only the combination of an agonist Ab to CD40 and IL-2, but neither agent administered alone, induced complete regression of metastatic tumor and specific immunity to subsequent rechallenge in the majority of treated mice. The combination of anti-CD40 and IL-2 resulted in significant increases in dendritic cell and CD8(+) T cell number in advanced tumor-bearing mice compared with either agent administered singly. The antitumor effects of anti-CD40 and IL-2 were found to be dependent on CD8(+) T cells, IFN-gamma, IL-12 p40, and Fas ligand. CD40 stimulation and IL-2 may therefore be of use to promote antitumor responses in advanced metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594303     DOI: 10.4049/jimmunol.170.5.2727

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Adapting Cancer Immunotherapy Models for the Real World.

Authors:  Lauryn E Klevorn; Ryan M Teague
Journal:  Trends Immunol       Date:  2016-04-19       Impact factor: 16.687

Review 2.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

3.  Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

Authors:  Chengwen Liu; Carol M Lewis; Yanyan Lou; Chunyu Xu; Weiyi Peng; Yan Yang; Alexander H Gelbard; Gregory Lizée; Dapeng Zhou; Willem W Overwijk; Patrick Hwu
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

4.  CD4⁺ and CD8⁺ T cell-dependent antiviral immunity requires STIM1 and STIM2.

Authors:  Patrick J Shaw; Carl Weidinger; Martin Vaeth; Kevin Luethy; Susan M Kaech; Stefan Feske
Journal:  J Clin Invest       Date:  2014-08-26       Impact factor: 14.808

5.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Authors:  Jonathan M Weiss; Jeff J Subleski; Tim Back; Xin Chen; Stephanie K Watkins; Hideo Yagita; Thomas J Sayers; William J Murphy; Robert H Wiltrout
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

7.  Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Authors:  Jonathan M Weiss; Lisa A Ridnour; Tim Back; S Perwez Hussain; Peijun He; Anna E Maciag; Larry K Keefer; William J Murphy; Curtis C Harris; David A Wink; Robert H Wiltrout
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

8.  Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

Authors:  Ana Lucia Dominguez; Joseph Lustgarten
Journal:  Vaccine       Date:  2009-11-18       Impact factor: 3.641

9.  Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.

Authors:  Kory L Alderson; Qing Zhou; Vanessa Berner; Danice E C Wilkins; Jonathan M Weiss; Bruce R Blazar; Lisbeth A Welniak; Robert H Wiltrout; Doug Redelman; William J Murphy
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

10.  Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Authors:  Arta M Monjazeb; Michael S Kent; Steven K Grossenbacher; Christine Mall; Anthony E Zamora; Annie Mirsoian; Mingyi Chen; Amir Kol; Stephen L Shiao; Abhinav Reddy; Julian R Perks; William T N Culp; Ellen E Sparger; Robert J Canter; Gail D Sckisel; William J Murphy
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.